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Abstract: This introductory minireview points out the importance of ion channels for cell 
communication. The basic concepts on the structure and function of ion channels triggered 
by membrane voltage changes, the so-called voltage-gated ion channels (VGICs), as well as 
those activated by neurotransmitters, the so-called ligand-gated ion channel (LGICs), are 
introduced. Among the most important VGIC superfamiles, we can name the voltage-gated 
Na+ (NaV), Ca2+ (CaV), and K+ (KV) channels. Among the most important LGIC super 
families, we can include the Cys-loop or nicotinicoid, the glutamate-activated (GluR), and 
the ATP-activated (P2XnR) receptor superfamilies. Ion channels are transmembrane 
proteins that allow the passage of different ions in a specific or unspecific manner. For 
instance, the activation of NaV, CaV, or KV channels opens a pore that is specific for Na+, 
Ca2+, or K+, respectively. On the other hand, the activation of certain LGICs such as 
nicotinic acetylcholine receptors, GluRs, and P2XnRs allows the passage of cations (e.g., 
Na+, K+, and/or Ca2+), whereas the activation of other LGICs such as type A γ-butyric acid 
and glycine receptors allows the passage of anions (e.g., Cl− and/or HCO3−). In this regard, 
the activation of NaV and CaV as well as ligand-gated cation channels produce membrane 
depolarization, which finally leads to stimulatory effects in the cell, whereas the activation 
of KV as well as ligand-gated anion channels induce membrane hyperpolarization that 
finally leads to inhibitory effects in the cell. The importance of these ion channel 
superfamilies is emphasized by considering their physiological functions throughout the 
body as well as their pathophysiological implicance in several neuronal diseases. In this 
regard, natural molecules, and especially marine toxins, can be potentially used as 
modulators (e.g., inhibitors or prolongers) of ion channel functions to treat or to alleviate a 
specific ion channel-linked disease (e.g., channelopaties). 
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1. Introduction  
The communication between individual neurons is performed at a morphologically and functionally 
highly specialized region named the synapse (reviewed in [111]). The name synapse was coined from 
the Greek syn, meaning “together”, and haptein, meaning “to clasp”. The synapse is structurally 
shaped by the presynaptic and the postsynaptic membrane both separated by the synaptic cleft. Figure 
1 shows a simple scheme of the synapse. A very interesting review on the mechanisms of vertebrate 
synaptogenesis has been recently published [104].  
 
 
Figure 1. Diagram showing the most important components of the synapse, including the pre- 
(axon terminal) and the post-synaptic cells (dendritic spine) and the synaptic cleft (taken from 
www.en.wikipedia.org/wiki/Synapse). CaV channels involved in neurotransmitter release, 
vesicles for neurotransmitter storage, and neurotransmitter re-uptake transporters are depicted 
in the presynaptic cell. Neurotransmitters are released from the presynaptic membrane to the 
synaptic cleft. Neurotransmitters reach the postsynaptic membrane by diffusion, and then 
activate neurotransmitter receptors. Neurotransmitter transporters are also shown in the 
presynaptic membrane. 
 
An important concept on the synaptic mechanism is that the transference of information between 
cells is achieved neither by a direct contact nor electrically but chemically. The chemo-electrical 
communication mechanism starts with the elicited action potential on the nerve ending which activates 
voltage-gated Na+ (NaV) channels (reviewed in [81]). The opening of voltage-gated Na+ channels 
depolarizes the presynaptic membrane. The depolarization process activates both voltage-gated Ca2+ 
(CaV) and K+ (KV) channels. On one hand, the opening of CaV channels enhances Ca2+ permeation in 
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the presynaptic membrane (reviewed in [84]). The raised intracellular Ca2+ concentration triggers a 
series of lipid membrane-vesicle fusion processes (reviewed in [91,101]) that finally produce 
neurotransmitter release. More specifically, the increase in intracellular Ca2+ activates calmodulin, and 
subsequently protein kinase C, which in turn phosphorylates other proteins that are involved in the 
process of vesicle mobilization, docking, and priming (reviewed in [104, 111]). On the other hand, the 
activation of KV channels provokes membrane hyperpolarization, stopping finally, the presynaptic 
action potential and thus, neurotransmitter release. Some ligand-gated ion channels (LGICs) with high 
permeability to Ca2+ (e.g., N-methyl-D-aspartate-subtype glutamate receptor and the α7 nicotinic 
acetylcholine receptor subtype) can also induce these intracellular processes (reviewed in [77]). A 
specialized region of the presynaptic membrane called “active zone” fuses with the neurotransmitter-
containing vesicles by means of different fusion proteins. Among these proteins we can name the 
synaptophysin-synaptobrevin complex, a hallmark of synaptic vesicle maturation (e.g., see [15]). The 
vesicles contain several additional fusion proteins located within its lipid membrane bilayer. After 
several decades of study, the fusion process is being understood (reviewed in [91,101,111]). Most 
steps after vesicle-membrane fusion are actually rationalized (reviewed in [29,39]). For example, it is 
known that after the vesicle content is released into the synaptic cleft the time course of 
neurotransmitter clearance is between 0.1 and 2.0 ms. The neurotransmitter molecules diffuse through 
the synaptic space in less than 0.2 ms reaching concentrations of 1-5 mM. Nevertheless, these 
parameters vary between synapses on a single neuron as well as among synapses from different 
neurons.  
Neurotransmitter release can be modulated by different molecular entities: (1) extracellular and 
intracellular messengers (reviewed in [42]), and/or (2) presynaptic receptors (reviewed in [49,59,74]). 
For instance, M2-type muscarinic receptors inhibit the release of the neurotransmitter acetylcholine 
(ACh) in the presynaptic membrane from the neuromuscular junction. The modulation of 
neurotransmitter release may lead to short- or long-term adaptations of the synapse to altered 
environmental signals (reviewed in [59,76]). Finally, the chemical information is converted into 
electrical currents on the postsynaptic membrane.  
The idea of chemical transmission started in the first decade of 1900 (e.g., see [61]), however, it 
took about 50 more years to be finally established. The molecules bearing chemical information were 
called neurotransmitters. Up to date, hundreds of neurotransmitters and neuropeptides have been 
identified as responsible for chemical signaling. In addition, it has been found that a single neuron can 
synthesize and liberate several of these substances at the same time. Different neurotransmitters 
operate at different parts of the nervous system and have different effects. Some promote the 
transmission of impulses while others inhibit it. At least three mechanisms modulating the 
neurotransmitter concentration in the synaptic cleft are well known: (a) enzymatic inactivation. For 
instance, the neurotransmitter ACh is catabolized to choline and acetate by neuronal 
acetylcholinesterases; (b) presynaptic membrane re-uptake by specific neurotransmitter transporters. 
Figure 1 shows neurotransmitter transporters. This mechanism is used for the re-uptake of monoamine 
neurotransmitters such as norepinephrine, epinephrine, dopamine, and serotonin (5-hydroxytryptamine; 
5-HT); and (c) soluble neurotransmitter-binding proteins. Several proteins homologous to the soluble 
ACh-binding protein (AChBPs) secreted by Lymnaea stagnalis glial cells [90] have been characterized. 
For instance, AChBPs from mollusks such as Aplysia californica [47] and Bulinus truncatus [24]. The 
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secretion of these proteins is modulated by the neurotransmitter itself [90] (reviewed in [89]). 
Functionally, they act as neurotransmitter carriers and they may buffer the neurotransmitter 
concentration in the synapse. Another potential function is that they may transport neurotransmitter 
molecules to extrasynaptic sites, allowing the interaction with, for instance, glial cells or other adjacent 
neurons. Similar binding proteins for other neurotransmitters might also exist in the central nervous 
system (CNS) from vertebrates. 
The postsynaptic membrane is highly specialized in the recognition and binding of 
neurotransmitters by means of lipid-embedded protein receptors. On the basis of their elicited 
physiological response two main receptor classes have been distinguished: ionotropic receptors and 
metabotropic receptors. The binding of one kind of neurotransmitter to its specific metabotropic 
receptor produces a slow biological response. The mechanism by which the activated receptor 
produces its final effect on the cell is mediated not directly but indirectly by the enzymatic interaction 
with one of the members of the G-protein family. An example of metabotropic receptor is the 
adrenergic receptor. On the other hand, the specific binding of a ligand to its ionotropic receptor 
induces a fast opening of the ion channel intrinsically coupled to the receptor. Figure 1 shows the 
location of postsynaptic ionotropic receptors. Interestingly, perisynaptic or extracellular ionotropic 
receptors have also been found (reviewed in [35,49,59]). The function of these receptors is not totally 
clear, but some perisynaptic receptor types may produce separate and sometimes opposite effects as its 
postsynaptic counterpart (reviewed [39,59]). 
2. Ion channels 
Ion flux across excitable cells mediated by activation of ion channels is a signaling mechanism that 
it is extensively used by different organisms from the three major superkindoms of life. Ion channels 
are responsible for generating and orchestrasting the electrical signals throughout the body. These 
signals ultimately modulate the thinking process in the brain, the heartbeat in the heart, and the muscle 
contraction in the muscle, to name only a few important physiological functions. Using methods such 
as molecular biology and electrophysiology, researchers have cloned, expressed, and characterized 
genes encoding many of these ion channels.  
Ion channels may be gated by different signals, including membrane voltage changes, mechanical 
forces, and chemicals. Ion channels that are triggered by specific endogenous ligands (e.g., 
neurotransmitters, neuropeptides, etc.) are called LGICs. LGICs are genetically, structurally, and 
functionally different from voltage-gated ion channels (VGICs). One of the main distinctions is that 
VGICs are gated not by endogenous ligands but by membrane voltage changes (reviewed in 
[17,81,95]).  
Several ion channels from different organs and tissues have been implicated in the pathophysiology 
of distinct diseases (reviewed in [2]). For instance, mutations in the epithelial chloride channel , CFTR 
(the cystic fibrosis transmembrane regulator), are responsible for cystic fibrosis, mutations in the renal 
chloride channel are responsible for hypercalciuric nephrolithiasis (Dent’s disease), truncation in the 
ATP-sensitive pancreatic potassium channel is involved in familial persistent hyperinsulinemic 
hypoglycemia from the infancy, mutations in the epithelial sodium channel are related with Liddle’s 
syndrome (produces hereditary hypertension and pseudoaldosteronism), mutations in the skeletal-
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muscle chloride channel are involved with different myotonias (e.g., Becker’s or Thomsen’s myotonia), 
mutations in the ryanodine calcium channel are related with the central core storage disease and with 
malignant hyperthermia. The list of the most important diseases related with VGICs or LGICs are 
provided in the following sections. 
In addition, ion channels are the targets of several marine toxins. One of the most important toxins 
from the point of view of their diversity and specificity are the snail toxins obtained from different 
Conus species. In this regard, Layer and McIntosh review, in this special issue, the most important 
structural details of these conotoxins as well as their therapeutical potential for the treatment of 
different diseases. 
3. Voltage-Gated Ion Channels 
Voltage-gated ion channels are complex proteins that are embedded in the lipid membrane of the cell. 
These channels conduct ions at very high rates (~1 million ions per second) and are regulated by the 
voltage across the membrane. The best known VGICs are NaV, KV, and CaV channels, as well as 
voltage-gated Cl− channels. This classification corresponds to the type of ion that each channel allows 
to pass. Subunits homologous to subunit α from the different VGICs form the structure of the ion pore. 
Subunit α also bears the voltage sensor that allows the channel to detect and gate in response to 
changes in the transmembrane voltage (reviewed in [17,95]). The opening of only one of these ion 
channels allows the passage of about 10 million ions per second (reviewed in [2]). In this regard, every 
time that a channel is open, a current of few picoamperes (pA) is generated (1 Ampere = 1 
coulomb/sec = 6.24×1018 electrons moving through a surface in one second). Since these channels are 
very efficient, there are only few thousand per cell of a given type. Consistent with the normal 
electrochemical gradients across the cell membrane for these ions, the opening of NaV or CaV channels 
induces membrane depolarization by allowing positive Na+ or Ca2+ ions flow into the cell. In contrast, 
the opening of KV or voltage-gated Cl− channels induces membrane hyperpolarization (K+ exits from, 
whereas Cl− enters, the cell, increasing the number of negative charges at the cytoplasmic surface of 
the membrane). Additional subunits (e.g., α2, β1, β2, and γ) from these ion channels have accessory 
functions. For instance, they modulate ion channel function, and interact with cytoskeleton proteins for 
anchoring as well as with protein kinases for phosphorylation processes.  
Given their physiological importance, VGICs are the targets for numerous small molecules and 
toxins of natural origin. Malfunctioning of these VGICs is implicated in many important diseases, and 
these ion channels are under intense scrutiny as potential targets for drugs for the treatment of different 
diseases. In this regard, Messerli and Greenberg, in this volume, review the effects of Cnidarian toxins 
(marine toxins) in VGICs. 
 
3.1. The Voltage-Gated Na+ Channel Superfamily 
Voltage-gated Na+ channels were purified from Electrophorus electricus electric organs in 1978 [3]. 
Since then, a good deal of information on the structure and function of different NaV channels has been 
obtained. Mammalian NaV channels from brain are structurally formed by three different subunits, α, 
β1, and β2, whereas channels formed by subunits α and β3 are present in dorsal root ganglia, and 
those comprised by subunits α and β1 are found in skeletal muscle (reviewed in [36,110]). There are at 
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least nine α subunits forming channels NaV1.1-NaV1.9. The Nomenclature Committee from the 
International Union of Pharmacology has recently reviewed and accepted a new nomenclature for NaV 
channel types [22,110].  
In the NaV channel structure, the α subunit, which makes up the core structure, is formed by four 
domains (I-IV), each containing six transmembrane segments (S1-S6) (reviewed in [17,110]). In 
contrast, each β1 and β2 subunit has just one transmembrane segment. Figure 2 depicts the schematic 
structure of the NaV channel. Interestingly, the ion-conducting pore of the channel is supported by the 
S5 and S6 transmembrane segments from the α subunit. The outer part of the pore is lined by a re-
entrant loop (the P loop) that links the transmembrane segments S5 and S6, while the C-terminal ends 
of the S6 segments line the cytoplasmic section of the pore. Certain amino acid residues in the C-
terminal segment of the P loop are critical for determining the conductance and ion selectivity of the 
Na+ channel. The activation gate is probably formed by the S6 segments at a point where they come 
into close apposition in the cytoplasmic half of the pore. The conformational change from closed to 
open is ultimately dependent on the motion of the positively charged, S4 segments, which act as 
voltage sensors by responding to changes in the electric field within the membrane. The 
transmembrane segment S4 is positively-charged and functions as a sensor for voltage changes across 
the lipid membrane. The activation of this sensor induces complex conformational changes in the 
protein that finally open the pore allowing the flux of Na+ into the cytoplasm of the cell. In vivo, Na+ 
influx produces a regenerative membrane depolarization in the millisecond time frame. The rapid 
depolarization activates both KV channels, which contribute to the rapid repolarizing phase of the 
action potential, and CaV channels. The activation of presynaptic CaV channels, in turn, induces 
neurotransmitter release. Figure 3B shows a voltage-clamp recording of NaV channel activity in 
response to a step depolarization of the membrane. 
NaV channels undergo cyclic conformational changes among at least three functionally different 
states. Figure 3A shows the three main conformational states. In the resting state, the ion channel is 
nonconducting. Membrane voltage changes trigger ion channel opening in the millisecond time regime. 
This conducting state is called the activated state. A few milliseconds after the initial activation of NaV 
channels, an intrinsic process of inactivation takes place in which the short intracellular loop 
connecting domains III and IV serves as the fast inactivation gate of the ion channel. This loop folds 
into the intracellular mouth of the ion pore and occludes it, ending the process of membrane 
depolarization as well as of neurotransmitter release. The hydrophobic residues isoleucine-
phenylalanine-methionine (IFM) are considered to serve as the inactivating domain. The inactivated 
state is a closed state which is distinct from the resting state. Although the channel inactivation process 
is mechanistically different from the desensitization found in LGICs, both processess produce similar 
modulatory effects on these ion channels. Finally, the gating process can be modulated by different 
protein kinases and phosphatases. Phosphorylation of the inactivation gate by protein kinase C slows 
inactivation, whereas phosphorylation of the intracellular loop between domains I and II by either 
protein kinase C or A reduces channel activation. Such modulations modulate patterns of electrical 
activity in neurons and other excitable cells. 
 
 




Figure 2. Schematic representation of the structure of the NaV channel (modified from [36]). 
(A) The α subunit consists of four homologous domains (I-IV), each containing six 
transmembrane segments (S1-S6). Positively-charged S4 segments [S4(+)] form the voltage 
sensor. Single segments and domains are connected by intracellular and extracellular loops. 
The intracellular loop between domain I and II presents several phosphorylation sites (P). 
Extracellular loops contain several glycosylation sites (Y). The isoleucine-phenylalanine-
methionine (IFM) motif has a crucial role in the process of channel inactivation. The 
inactivation gate is depicted in red and includes the IFM motif. (B) Transmembrane 
arrangement of domains I-IV (DI-DIV) around the ion pore, seen from the cytoplasmic end. 
The inactivation gate is depicted in red, close to the IFM motif [see (A)]. (C) Binding sites (1-5) 
for different ligands [e.g., tetrodotoxin (TTX)] as well as for local anesthetics (LAs). The 
selectivity filter is depicted in blue. 
 
Different mutations in NaV channels are implicated in several diseases, the so-called 
“channelopathies”, from the muscle, heart, or nervous system (reviewed in [2,41,110]). For example, 
mutations in cardiac NaV1.5 channels are responsible for long-QT type 3 and Brugada syndromes 
which produce cardiac arrhythmias, whereas mutations in the skeletal-muscle NaV1.4 channel are 
implicated in “hyperkalemic periodic paralysis” (a muscle weakness disorder aggravated by high K+), 
in Masseter-muscle rigidity (succinylcholine-induced), as well as in different kinds of myotonias (e.g., 
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paramyotonia congenital, a syndrome of cold- and exercise-induced muscle stiffness). In addition, 
mutations in the neuronal NaV1.1 channel produce “generalized epilepsy with febrile seizures plus, 
type II”, whereas mutations in the β1 subunit produce “generalized epilepsy with febrile seizures plus, 
type I”. Finally, knockout mice lacking the NaV1.8 channel are viable but their response to pain is not 
normal. 
 
Figure 3. Functional properties of NaV channels (modified from [41]). (A) Schematic 
representation of a NaV channel undergoing the major gating transitions (resting ↔ open ↔ 
inactivated). (B) Voltage-clamp recording of NaV channel activity in response to membrane 
depolarization. Downward deflection of the current trace (red) corresponds to inward 
movement of Na+. 
 
NaV channels are targets for the action of natural as well as synthetic drugs (reviewed in [2,36,37]). 
Among clinically important synthetic drugs we can name anticonvulsants (e.g., carbamazepine, 
phenytoin, and valproic acid), local anesthetics (e.g., bupivacaine, cocaine, lidocaine, mepivacaine, 
and tetracaine), as well as Class IA (e.g., disopyramide, procainamide, and quinidine), Class IB (e.g., 
lidocaine, mexiletine, phenytoin, and tocainide), and Class IC antiarrhythmics (e.g., encainide, 
flecainide, and propafenone). Recent research efforts have focused on the development of analgesic 
agents which selectively block dorsal root ganglion sodium channels that are involved in transmission 
of pain sensation.  
NaV channels present at least six binding sites for synthetic and natural molecules (Sites 1-6, as well 
as the binding site for local anesthetics) that are located in different domains throughout the protein 
(reviewed in [36]). Table 1 shows the most important natural molecules including marine toxins that 
affect NaV channels. Natural drugs targeting NaV channels are chemically very diverse and include 
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polypeptides, alkaloids, cyclic polyethers, esters, and heterocycles. For example, the reversible 
blockers tetrodotoxin (from puffer fish and related species from the Tetraodontidae family), 
maculotoxin (actually tetrodotoxin present in the blue-ringed octopus Hapalochlaena maculosa), 
saxitoxin (from different algal species of the order Dinoflagellata such as Alexandrium tamarense, 
Gymnodinium catenatum, and Pyrodinium bahamense, as well as from certain freshwater 
cyanobacteria), and µ–conotoxins GIIIA, GIIIB, and GIIIC (polypeptides from the marine snail Conus 
geographus) and PIIIA (from C. purpurascens) bind to Site 1. Certain amino acids from the pore 
lining in the extracellular mouth of the ion channel are critical for the binding of these toxins. The 
main pharmacological action of these toxins is to block current flow through the pore thus, decreasing 
membrane depolarization and, as a consequence, also inhibiting neurotransmitter release. The toxic 
effects induced by these toxins include diarrhea, vomiting, paralysis, paraesthesia, dyspnea, 
hypotention, convulsions, mental impairments, cardiac arrhythmia, respiratory failure, and finally 
death.  
Local anesthetics also block the ion channel but its binding site is located in a different domain 
from that for Site 1. Interestingly, local anesthetics pharmacologically behave as noncompetitive 
antagonists (NCAs) of nicotinic acetylcholine receptors (AChRs) (reviewed in [9,12]). Batrachotoxin 
(alkaloid from the skin of Colombian arrow poison frogs of the genus Phyllobates), veratridine 
(alkaloid from plants of the Liliaceae family), aconitine (alkaloid from the plant Aconitum napellus), 
and grayanotoxin (diterpenes from several Rhododendron species) bind to Site 2. The main action 
elicited by these drugs is to produce persistent channel activation. In the heart, batrachotoxin, 
veratridine, and grayanotoxin, but not aconitine, produce positive ionotropic effects (i.e., increased 
contraction force). Class 1 scorpion α-toxins (from the genera Buthus, Androctonus, and Leiurus), δ-
atracotoxins (from Australian funnel web spiders of the Atracinae family such as Atrax robustus which 
produces robustoxin and Hadronyche versutus that produces versutoxin), µ-agatoxin-I and -IV (from 
the web spider Agelenopsis aperta), sea anemone toxins (from the genera Anthopleura and Anemonia), 
several toxins from the spider Phoneutria nigriventer, and δ–conotoxins such as PVIA (from C. 
purpurascens) as well as TxVIA (also called King-Kong peptide TxIA), TxIB, and TxIIA (from C. 
textile neovicarius) bind to Site 3. This site is located in the loop formed between the transmembrane 
segments S3 and S4 from domain IV. The main pharmacological effects of these toxins are to slow 
inactivation, and/or enhance or prolong activation. Persistent channel activation sustains membrane 
depolarization, enhancing neurotransmitter release, leading to rigid paralysis and, finally, death. 
Toxins that bind to Site 3 enhance the activity of molecules acting on Site 2. Scorpion β-toxins from 
the genus Centuroides bind to Site 4. Class 2 Scorpion β-toxins shift the voltage-dependence of 
activation to more negative membrane potentials without modifying the channel inactivation process, 
whereas Class 3 Scorpion β-toxins alter the voltage-dependence of both activation and inactivation. 
The lipid-soluble polyether marine toxins brevetoxins (produced by the dinoflagellate Karenia brevis) 
and ciguatoxins (from several dinoflagellate species including Gambierdiscus toxicus) bind to Site 5. 
The effects elicited by these NaV channel activators include repetitive neuronal firing, shifting the 
voltage-dependence, and blocking the channel inactivation process. Finally, insecticides such as 
pyrethroids (from the flowers of certain Chrysanthemum species) and dichlorodiphenyltrichloroethane 
(DDT) bind to Site 6, a poorly defined binding domain. These compounds produce hyperexcitability 
and paralysis preferentially in invertebrates rather than in mammals. Sites of action of fast inactivation 
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inhibitors such as pronase, N-bromoacetamide and chloramine-T have not been positively identified as 
well as for prolongers including DPI 201-106 and BDF9148 that are in experimental stage as 
therapeutics for the treatment of congestive heart failure. Finally, the location of binding sites for other 
natural toxins are still under debate. These include homobatrachotoxin (steroidal alkaloids from birds 
of the genus Pitohui) which activates NaV channels, and phoneutriatoxins (from the Banana spider 
Phoneutria nigriventer) as well as α- and β-pompilidotoxins (from the solitary wasps Anoplius 
samariensis and Batozonellus maculifrons) which slow the NaV channel inactivation process.  
 
Table 1. Binding site location for different toxins and drugs on the NaV channel. 
 
Bindig Site Toxin/Drug (origin) Pharmacological Effect 
1 Tetrodotoxin (marine) 
Saxitoxin (marine) 
µ-Conotoxins GIIIA and GIIIB (marine) 
Ion channel block 





3 Scorpion α-toxins (animal) 
Sea anemone toxins (marine) 
δ-Atracotoxins (animal) 
δ–Conotoxins PVIA,  
TxIA, TxIB, and TxIIA (marine) 
Slow inactivation 
Enhancement of persistent activation 
4 Scorpion β-toxins (animal) Shift voltage-dependent activation to 
more negative potentials 
5 Brevetoxins (marine) 
Ciguatoxins (marine) 
Shift voltage-dependent activation to 
more negative potentials 
6 Pyrethroids (plant) 
DDT (synthetic) 
Slow activation, inactivation and 
deactivation processes 
Local anesthetic Local anesthetics  
[synthetics in general; plant product (e.g., 
cocaine)] 
Ion channel block (use-dependent) 
Additional binding 
sites 
DPI 201-106 (synthetic) 
BDF9148 (synthetic) 









Disruption of fast inactivation 
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In this special issue, French and collaborators review the general aspects of the structural and 
functional properties of marine toxins that interact with NaV channels. In addition, Geffeny and Ruben 
cover the information regarding the specific interaction of tetrodotoxin with NaV channels, and finally 
Nicholson and Lewis present updated information regarding the pharmacological effects of 
ciguatoxins on NaV channels. 
3.2. The Voltage-Gated Ca2+ Channel Superfamily 
CaV channels were first identified in crustacean muscle fibers by Fatt and Katz [40]. The use of 
molecular biology has helped to identify subclasses of these channels in all types of excitable cells in 
vertebrates and invertebrates, and even in plants. CaV channels can be classified depending on their 
activity or site of activity. For instance, in neurons, CaV2.1 and CaV2.2 channels are located 
presynaptically and are involved in neurotransmitter release. Almost all other types have been found in 
cell bodies and dendrites. The currently accepted nomenclature for CaV channels is found in Catterall 
et al. [23], and summarized here in Table 2.  
CaV channels are structurally formed by several subunits including α1, α2, δ, β, and γ (reviewed in 
[95,109]). The α1 subunit is formed by six transmembrane segments, and contains the ion channel, the 
voltage sensor, and the gate. This structural arrangement is shown in Figure 4, and it is similar to NaV 
channels (see Fig. 2). The β subunit is located intracellularly and it is involved in membrane 
trafficking of α1 subunits. The α2 subunit is a highly glycosylated extracellular protein that is attached 
to the membrane-spanning δ subunit by means of disulfide bonds. The α2 subunit provides structural 
support, whereas the δ subunit modulates the voltage dependent activation and steady-state 
inactivation processes. The γ subunit is a glycoprotein having four transmembrane segments.  
The biophysical properties of these channels were studied by using voltage- and patch-clamp 
methods. CaV channels are normally closed at resting membrane potentials, and open upon membrane 
depolarization. The resultant current through the cell membrane can be characterized by a number of 
properties including the membrane potential range over which the channel reaches its maximum open 
probability as well as the current kinetics. The use of selective drugs and toxins has helped to identify 
specific current components observed in an entire cell that correspond to a particular channel type. 
There is accumulating evidence to support the view that CaV channels are implicated in several 
diseases and channelopathies (reviewed in [2]). For instance, autoantibodies against P/Q-type CaV 
channels are produced in the Lambert-Eaton syndrome, reducing the number of these channels in the 
presynaptic cell and provoking myasthenic syndrome (i.e., muscle weakness). Mutations in 
dihydropiridine-sensitive CaV channels, more specifically in the S4 region, are related with the muscle 
disorder “hypokalemic period paralysis”. Other mutations have been implicated in diseases such as 
spino-cerebellar ataxia (type 6), familial hemiplegic migraine, episodic ataxia (type 2), and X-linked 
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Current Tissue Localization Drugs (origin) Pharmacological effect 
CaV1 Channels 






CaV1.2 L Cardiac myocytes 
Endocrine cells 








CaV1.3 L Endocrine cells 







CaV1.4 L Retina Not established Neurotransmitter release 
CaV2 Channels 
 
CaV2.1 P/Q Nerve terminals and 
dendrites 
ω-Agatoxins IVA and IVB (animal) Inhibits neurotransmitter 
release 
CaV2.2 N Nerve terminals and 
dendrites 




CaV2.3 R Neuronal cell bodies and 
dendrites 
SNX-482 (animal) Inhibits repetitive firing 
CaV3 Channels 
 






Inhibits repetitive firing 
Inhibits pacemaker 






Inhibits repetitive firing 
Inhibits pacemaker 





Inhibits repetitive firing 
 








Figure 4. Schematic representation of the structure of the CaV channel (taken from 
www.omedon.co.uk/ionchan/channels/calcium). The α1 subunit consists of four homologous 
domains (I-IV; depicted in different colors), each containing six transmembrane segments (S1-
S6). This subunit contains the ion conducting pore, the voltage sensor, and the gate. The β 
subunit is located intracellularly and it is involved in membrane trafficking of α1 subunits. The 
α2 subunit is attached to the membrane-spanning δ subunit by means of disulfide bonds. The 
α2 subunit provides structural support, whereas the δ subunit modulates the voltage-dependent 
activation and steady-state inactivation processes. The γ subunit is a glycoprotein having four 
transmembrane segments. 
 
Different CaV channel families are targets for distinct therapeutically relevant drugs (reviewed in 
[2,37,109]). Table 2 shows the pharmacological effect of several drugs including marine toxins on 
different CaV channels. For instance, the CaV1 channel family (L-type currents) is the target for the 
pharmacological action of different drugs used in the treatment of cardiovascular diseases including 
phenylalkylamines, dihydropyridines, and benzothiazepines (class IV antiarrhythmics). Interestingly, 
these classes of drugs bind to different sites. Phenylalkylamines (e.g., verapamil, devapamil, 
gallopamil, and thiapamil) enter the pore from the cytoplasmic side and bind to a site located at 
segment S5 from domain IV, similar to that for local anesthetics in the NaV channel, and occlude the 
pore. Dihydropyridines (e.g., nifedipine, nicardipine, nitrendipine, nimodipine, nisoldipine, and 
felodipine) inhibit the ion channel by an allosteric mechanism. This site is formed by segment S6 from 
domains III and IV and segment S5 from domain III. Other dihydripyridine derivatives (e.g., Bay 
K8644) activate CaV channels producing vasoconstriction and positive ionotropic effects. 
Benzothiazepines (e.g., diltiazem) access the channel from the extracellular side and bind to a site 
located close to the extracellular mouth. Snake toxins such as calcicludine and calciseptine (from 
Dendroaspis angusticeps) as well as TaiCatoxin (from Oxyuranus scutellatus scutellatus) are also 
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potent and selective blockers of L-type channels. The CaV2 channel family is specifically blocked by 
spider and marine snail toxins. For example, ω-agatoxins IVA and IVB (from the funnel web spider 
Agelenopsis asperta) as well as ω-conotoxins MVIIC and MVIIA (from C. magus) inhibit the gating 
process in CaV2.1 channels (P/Q-type currents), whereas ω-conotoxins GVIA (from C. geographus) 
blocks CaV2.2 channels (N-type currents). Since SNX-482 (from the tarantula Hysterocrates gigas) 
specifically inhibits CaV2.3 channels, this toxin was crucial for the characterization of R-type currents. 
A polyamine with analgesic properties obtained from the fishing spider Dolomedes okefinokensii 
reversibly blocks L-and R-type CaV channels. 
On the other hand, the activation gating on CaV3 channels (T-type currents) is inhibited by kurtoxin 
(obtained from South African scorpions). Mibefradil and pimozide block CaV3 channels slightly more 
strongly than either CaV1 or CaV2 channels. In addition, ω-grammotoxin SIA (obtained from the South 
American rose tarantula Grammostola spatulata), HWTX-I (obtained from the Chinese bird spider), 
taicatoxin (obtained from the Australian Taipan snake), and several spider toxins from Phoneutria 
ngriventer, block different CaV channels as well.  
Regarding CaV channel marine toxins, Schroeder and Lewis cover the effect of ω-conotoxins and 
their therapeutical applications, whereas Zhang is reviewing different aspects of the interaction of SO-
3 conotoxins with N-type CaV channels. 
 
3.3. The Voltage-Gated K+ Channel Superfamily 
The first KV channel sequence was determined from the Shaker mutant of Drosophila melanogaster 
in 1987 [94]. Since then, a great effort has been done to elucidate the structural arrangement of this 
channel family that recently culminated in the crystallographic structure of the mammalian Shaker KV 
channel [71]. KV channels are more diverse and widespread than other ion channel families (reviewed 
in [76]). In this regard, KV channels have been divided in nine families (e.g., KV1-KV9) (reviewed in 
[95]). KV1-KV4 channels are also called Shaker, Shab, Shaw, and Shal, respectively. The current 
nomenclature for these channels is found in Gutman et al. [46]. Regarding their assembly properties, 
families KV1-KV4 can form homomeric or heteromeric channels, whereas families KV5-KV9 cannot 
form homomeric channels but interact with members from the KV2 family to form heteromeric 
channels. This is why subunits KV5-KV9 are called modulatory subunits.  
Figure 5 depicts the most important structural features of a prototypic KV channel. KV channels are 
composed of four separate α subunits, each containing six transmembrane segments (S1-S6) (reviewed 
in [95]). The α subunits are assembled as a tetramer to form a central pore that is specific for K+ ions. 
Four accessory β subunits (e.g., β1 and β2) may be complexed with the α subunits in a stoichiometry 
α4β4 to form the functional KV channel. The α subunit determines the basic gating properties. More 
specifically, the peptide chain (H5 or loop P) between segments S5 and S6 lines the water-filled 
channel pore. This region is highly conserved in all VGICs. Mutations in this region alter the 
permeation properties of the ion channel. As for NaV channels, KV channels have an S4 segment, 
bearing a cluster of positively-charged residues (e.g., lysines and arginines), that serves as the voltage 
sensor. Voltage-dependent fast inactivation (N-type) of the channel is mediated by a long chain of 
amino acids with a ball in the amino terminal that swings into the mouth of the ion channel and blocks 
the permeation pathway from the cytoplasmic side (i.e., the “ball and chain” model). Several residues 
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Figure 5. Schematic representation of the structure of the KV channel (modified from [2]). (A) 
Each α subunit consists of six transmembrane segments (S1-S6). Positively-charged amino 
acids (e.g., lysine and arginine) in the S4 segment form the voltage sensor. Key residues lining 
the channel pore (H5 or P loop) are found between S5 and S6. The “ball and chain” structure at 
the N-terminal participates in N-type “fast inactivation”, occluding the permeation pathway, 
whereas certain residues at S6 are involved in the C-type “slow inactivation” process. Several 
phosphorylation sites (P) are present in the C-terminal domain. (B) The proper KV channel is 
assembled by the interaction of four α subunits. The pore region appears to have wide 
intracellular and extracellular vestibules (~28-34 Å wide and 4-8 Å deep) that lead to a 
constricted pore of 9-14 Å in diameter at its entrance, tapering to a diameter of 4-5 Å at a depth 
of ~6 Å from the vestibule. K+ ions (small green balls) are passing through the ion filter from 
the cytoplasmic to the extracellular side of the ion channel (efflux). 
 
KV channel mutations are implicated in several important diseases (reviewed in [76]). Among them 
we can name cardiac arrythmias (e.g., long-QT syndromes), congenital deafness, epilepsy, diabetes, 
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misregulation of blood pressure, multiple sclerosis, Alzheimer's disease and other dementias, migraine, 
pain, anxiety and bipolar disorder. 
KV channels are also the target of several synthetic and natural drugs (reviewed in [2,37,54,86]). 
Among synthetic drugs we can name antidiabetic drugs (e.g., glipizide, glyburide, and tolazamide), 
antihypertensive drugs (e.g., diazoxide and minoxidil), and Class III antiarrhythmics (e.g., amiodarone, 
clofillium, dofetilide, and sotalol). Among nonselective blockers we can include inorganic cations (e.g., 
Li+, Cs+, Ba+, Hg+, and Zn2+) and quaternary ammonium derivatives (e.g., tetramethy-, tetrahethyl-, 
tetrabutyl-ammonium derivatives). Aminopyridines (e.g., 4-aminopyridine, and 3,4-diaminopyridine) 
are more selective drugs in clinical trial for the treatment of long-standing spinal cord injury. These 
drugs assist recovery of sensory and motor functions, enhance pulmonary functions, and diminish 
muscle spasticity.  
Regarding natural toxins, Scorpionidae toxins including charybdotoxin (obtained from Leiurus 
quinquestriatus hebraeus), agitoxin-2 (obtained from Leiurus quinquestriatus hebraeus), margatoxin 
(obtained from Centruroides margaritatus), noxiustoxin (obtained from Centruroides noxius), 
anuroctoxin (obtained from Anuroctonus phaiodactylus), tityustoxin-Kα and -Kβ (obtained from the 
Brazilian scorpion Tityus serrulatus), hongotoxin-1 (isolated from Centruroides limbatus), and 
parabutoxin-3 (obtained from Parabuthus transvaalicus) selectively block KV channels. For instance, 
parabutoxin 3 and hongotoxin-1 block several KV1 channels, whereas margatoxin, noxiustoxin, and 
agitoxin-2 prefer the KV1.3 subtype. Agitoxin-2 interacts with the outer vestibule of the ion channel. 
Several snake toxins such as α- and β-dendrodotoxin [obtained from green (Dendroaspis viridis) and 
black mamba (Dendroaspis polylepis)] are KV channel blockers as well. Unlike scorpion toxins which 
act by pore occlusion, spider toxins appear to bind to four equivalent sites at the surface of the KV 
channel (one per subunit) close to the voltage sensor and thus, modify the gating process. Among them, 
we can include phrixotoxin-1 (obtained from the Chilean fire tarantula Phrixotrichus auratus), 
stromatoxin (obtained from Stromatopelma calceata), hanatoxin-1 and -2 (obtained from the Chilean 
rose tarantula Grammostola spatulata), heteropodatoxin-2 (obtained from the huntsman spider 
Heteropoda venatoria), as well as heteroscodratoxin-1 and -2 (obtained from Heteroscodra maculata). 
These toxins inhibit KV2 and KV4 channel families. Other natural toxins include MCD peptide 
(obtained from the honeybee Apis mellifera) which has high affinity for KV1.1, KV1.2, and KV1.6 
channel subtypes, stichodactyla toxin (obtained from the sea anemone Stichodactyla helianthus), 
phalloidine (alkaloid obtained from the death-cap mushroom Amanita phalloides), and correolide 
derivatives (triterpenes purified from the root and bark of the Costa Rican tree Spachea correae) that 
are selective blockers of KV1 channels and may be used as immunosuppressants by inhibiting the 
lymphocyte KV1.3 channel. Among marine toxins we can name κ-conotoxin PVIIA (obtained from C. 
purpurascens) which is the first identified marine toxin that blocks Drosophila KV channels. However, 
no mammalian channel has been shown to be sensitive to the action of this conotoxin. Interestingly, a 
new member from the I-conotoxin superfamily, conotoxin ViTx (obtained from C. virgo), inhibits the 
vertebrate channels KV1.1 and KV1.3 but not KV1.2 [53], whereas conkunitzin-S1 (obtained from C. 
striatus) and 6-bromo-2-mercaptotryptamine (obtained from the marine snail Calliostoma 
canaliculatum) interact with the Shaker KV channel. Ciguatoxin-1 (obtained from the dinoflagellate 
Gambierdiscus toxicus) is also a blocker from these ion channels. In general, these blockers prolong 
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the duration of presynaptic action potentials in neurons, increasing Ca2+ influx by indirect CaV 
activation, enhancing neurotransmitter release and subsequently, provoking strong convulsions. 
4. Ligand-Gated Ion Channels 
Among LGIC receptors, four different superfamilies have been described in detail, namely the Cys-
loop or nicotinicoid receptor superfamily, the ionotropic glutamate receptor (GluR) superfamily, the 
ATP-activated receptor (P2XnR) superfamily (reviewed in [7,8,69]), and the transient receptor 
potential-canonical channels (reviewed in [102]). These receptor superfamilies are considered different 
from each other based upon genetical, structural, and functional properties. An updated data base for 
the LGIC receptor superfamilies can be found in the following web page: 
www.pasteur.fr/recherche/banques/LGIC/LGIC.html (see [64,65]). 
 
4.1. Structural and Functional Similitude Among LGIC Superfamilies 
Although the Cys-loop receptor, the GluR, and the P2XnR superfamily are genetically and 
structurally different among them, all receptor members present at least some common features. Figure 
3 shows the most important structural characteristics that are preserved throughout the different LGIC 
receptor superfamilies. From the structural point of view, we can generalize that these LGIC receptor 
superfamilies are formed by three main modules: a large extracellular portion, the transmembrane 
portion, and a smaller cytoplasmic portion. The extracellular domain contains the neurotransmitter 
binding sites and several consensus sequences involved in glycosylation. The transmembrane domain 
has two faces, one internal face that is mainly related with the formation of the intrinsic ion channel 
and another external face which interacts with the lipid membrane. The aqueous pore allows the 
passage of different cations or anions across the cell membrane finally producing excitatory (for cation 
flux) or inhibitory (for anion flux) cell responses. The cytoplasmic portion serves as a structural link to 
cytoskeleton proteins for receptor anchorage, clustering, stabilization, and assembly (reviewed in [50]). 
This domain is also related with receptor modulation (e.g., desensitization) by phosphorylation-
dephosphorylation processes (e.g., reviewed in [19,49,56,58,93]). 
From the functional point of view, LGIC receptor superfamilies also have some basic aspects that 
are common among them. LGIC superfamilies present a very simple repertoire of functional properties. 
Each receptor recognizes its specific neurotransmitter, and upon binding, the intrinsically-coupled ion 
channel is opened, augmenting in turn the possibility of ions to cross the lipid membrane. Thus, after 
channel opening, a new ionic concentration is found at the aqueous solutions bathing the opposed 
faces of the lipid bilayer of the cell. In particular, the cytoplasmic compartment will have a higher 
content of Na+ or Ca2+ (for cation channels) or of Cl– or HCO3– (for anion channels). The increased 
cation concentration in the cytoplasm produces membrane depolarization, whereas the increased anion 
concentration in the cytoplasm induces membrane hyperpolarization.  
Considering the high level of complexity of the neuronal network, the activation of certain cation 
ion channels can result however in either neuronal inhibition or disinhibition (reviewed in [4]). The 
opposite is also true, the activation of certain anionic channels may finally produce membrane 
depolarization in immature neurons (e.g., see review by [39]). 
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In general, these receptor superfamilies are functionally involved in higher order brain mechanisms 
such as cognition, learning, memory, and behavior, as well as in peripheral functions including muscle 
contraction, bone formation, cardiac and gastrointestinal modulation, embryonic development, sensory 
perception, nociception, and pain processing (reviewed in [38,43,49,70,103]). The malfunctioning of 
these receptors has been considered as the origin of several neurological disorders as well as drug 
addiction (e.g., see [38,43,49,70,103]). 
All these biologically relevant receptor properties are triggered by the binding of the specific 
neurotransmitter. Upon binding, the receptor protein undergoes several conformational changes. 
Several lines of experimental evidence suggest the existence of a high number of intermediate states 
(reviewed in [8,26,30,82]). To make it simpler, however, we will assume that receptors exist in a 
minimum of three interconvertible states. The diagram indicating the existence of at least three 
receptor states is shown in Fig. 6. In the absence of the specific neurotransmitter, most receptors are in 
the resting state (R). The diagram shows a generalized receptor with just one neurotransmitter binding 
site. However, up to five binding sites may exist for pentameric receptors formed by just one subunit 
subtype (e.g., homomeric receptors). The resting state is defined by the existence of a closed ion 
channel. Nevertheless, the receptor is still activatable. In this regard, the receptor is activated (A) in the 
presence of the neurotransmitter, and the ion channel is opened in a very fast time frame (R → A). The 
time regime is different among receptor subtypes. Although ion channels open with higher probability 
in the presence of agonists, thermodynamics fluctuations also allow ion channels to be open but with 
much lower probability (e.g., see review by [39]). In the prolonged presence of the neurotransmitter, 
the activated receptor is concomitantly commuted to a desensitized state (D) in a timescale that in 
general is slower than the activation process (A → D). Neither a specific energy source nor an ionic 
gradient is needed to induce the R → A → D conformational shift. The desensitized state is refractory 
to the pharmacological action of the neurotransmitter or other agonists, and in this case the ion channel 
remains closed. In addition, the desensitized state has a relatively higher affinity for the specific 
neurotransmitter as well as for other agonists and some antagonists than that in the resting state. 
Different receptor subtypes have distinct desensitized rates and each receptor may present various 
desensitized states. For instance, the AChR α7 subtype presents a fast desensitization rate, whereas the 
α2β2 subtype practically does not desensitize. In general, the desensitization process is a reversible 
process: after agonist washout, the receptor can be activated again (D → R). The receptor can recover 
from the desensitized state by means of at least two pathways: a ligand-bound receptor can reopen, or 
the neurotransmitter dissociates first and then the receptor can return to the resting state. 
Desensitization is a classical example of allosteric protein behavior that considers the previous 
existence of discrete conformational states. Physiologically, desensitization might be a major 
determinant of synaptic efficacy by controlling the number of available receptors (reviewed in [82]).  
5. The Cys-Loop or Nicotinicoid Receptor Superfamily 
This superfamily is called “Cys-loop receptor superfamily” because all receptor members conserve 
a 15-residue-spaced disulfide loop between amino acids 128 and 142 (corresponding to the AChR α1 
subunit) located in the extracellular domain of the receptor. Figure 7 shows the most important 
structural characteristics of the Cys-loop receptor superfamily, and its distinction with the ionotropic 
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GluR and P2XnR superfamilies. More recently, the term “nicotinicoid receptor superfamily” has been 
imprinted. Examples of this kind of receptors are the members of four families of ion channel-coupled 
receptors which are gated by specific neurotransmitters, including type A and C GABA receptors 
(GABAAR and GABACR), glycine receptors (GlyRs), type 3 5-HT receptors (5-HT3Rs), and both 
neuronal- and muscle-type nicotinic receptors (AChRs) (reviewed in 
[7,8,13,14,30,32,55,63,67,69,75,78]). The hirerarchy for the different LGIC receptor superfamilies is 







Figure 6. Diagram showing the general dynamics of multiple conformational states on LGIC 
receptor superfamilies. In the absence of neurotransmitter molecules (shown here as red 
triangles), the receptor is in the resting state. The receptor is shown here bearing just two 
neurotransmitter binding sites, but there is evidence indicating that up to five binding sites may 
exist. In the resting state, the ion channel is closed but the receptor is still activatable. After 
neurotransmitter binding, the receptor is activated and the ion channel is opened, allowing the 
passage of different ions across the lipid membrane. In general, the agonist affinity for the 
activated receptor is relatively lower (shown here as a loosed interaction between the 
neurotransmitter and its binding site) than that in the desensitized state (shown here as a tight 
interaction between the neurotransmitter and its binding site). The transition from the resting to 
the activated state is relatively fast, but the time regime is different among receptor subtypes. 
In the prolonged presence of the neurotransmitter, the receptor becomes refractive to the 
pharmacological action of the neurotransmitter molecule and thus, its ion channel is closed. 
Different receptor subtypes have distinct desensitized rates and various desensitized states. In 
general, the desensitization process is a reversible process: after agonist washout, the receptor 
can be activated again. The receptor can recover from the desensitized state by means of at 
least two pathways: a ligand-bound receptor can reopen, or the agonist dissociates first and 
then the receptor can return to the resting state. 
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Table 3: Hierarchy of ligand-gated ion channel receptor superfamilies. 
Superfamily of Cys-Loop or Nicotinicoid Receptors 
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Figure 7. Schematic representation of the structural organization of the Cys-loop receptor, 
GluR, and P2XnR superfamilies. (A) Schematic illustration of the primary sequence of several 
subunits from members of the Cys-loop receptor superfamily, including α (α1-α10) an non-α 
(β1-β4, γ, ε, and δ) subunits from the AChR, the 5-HT3AL subunit from the 5-HT3R, the α1 
subunit from the GABAAR, and the α1 subunit from the GlyR. M1-M4, transmembrane 
domains; C⎯C, Cys-Cys bridge found in the Cys-loop ion-channel superfamily (homologous 
to Cys128 and Cys148 of the α1 AChR subunit); CC, Cys-Cys pair found in the α subunits from 
both muscle- and neuronal-type AChRs (corresponding to Cys192-Cys193 from the α1 AChR 
subunit); Υ, oligosaccharide groups. (B) Diagram of the tertiary and quaternary organization of 
the LGIC receptor superfamilies. AChR subunits are formed by a long N-terminal hydrophilic 
extracellular region; four highly hydrophobic domains (M1-M4). The intrinsic ion channel is 
composed by five M2 segments, one from each subunit. Moreover, M1-M2 and M2-M3 are 
connected by minor hydrophilic stretches; and a major hydrophilic segment (M3-M4 loop) 
facing the cytoplasm. Additionally, the M4 domain orientates the C-terminus to the synaptic 
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side of the membrane. On the contrary, GluR subunits present three transmembrane domains 
(Ml, M3, and M4) and a reentrant loop (P), as well as a cytoplasmic orientation for the COOH-
terminus; while the P2XnR subunits have only two transmembrane domains (Ml and M2) and 
both N- and C-terminus are cytoplasm oriented. (C) Schematic representation of the oligomeric 
organization for LGIC receptor superfamilies. The hypothetical pentameric AChR is formed by 
two α subunits and three non-α chains. The two ligand binding sites (L) are located at the 
interfaces of one α subunit and one non-α chain. Regarding homomeric AChRs (e.g. α7, α8, 
and α9), up to five ligand binding sites may putatively exist. On the contrary, GluRs present 
four ligand binding sites, each one located in a lobe formation from each subunit, whereas 
P2XnRs only have three ligand binding sites, each one located on one subunit. 
 
 
Apart from the fact that all receptors from this superfamily have a 15-residue Cys-loop, they also 
share some structural and functional features that make them a true superfamily of receptors. Among 
the most important structural and functional features, we can name:  
(1) High homology in amino acid [63,66] and pair base [78] sequence. Homology of ~30% is 
observed among different subunits, whereas ~70% homology is obtained considering just one 
subunit from different species. The genetic evidence also suggests that all members have evolved 
from the same ancestor protein [63,66,67,78].  
(2) A pentameric quaternary structure. This structural characteristic has been confirmed by 
electron microscopy of tubular crystals of native membranes containing high density of AChRs 
prepared from Torpedo electric organs. The enduring effort from Unwin’s laboratory has recently 
rendered a receptor three-dimensional image with a resolution of 4 Å [99]. 
(3) A large N-terminal domain formed by ~220 residues located extracellularly, bearing the 
neurotransmitter binding sites. This funnel-shaped domain has an outer diameter of 70-80 Å and 
protrudes ~60 Å above the lipid membrane surface. This domain had been previously modeled 
mainly as antiparallel β-sheet secondary structures arranged perpendicular to the membrane 
surface [66]. This model was recently confirmed by determining the crystallographic structure of 
the AChBP from L. stagnalis [20], which resembles the extracellular portion of the AChR, in 
particular the α7 homomeric receptor, by 24%.  
(4) An interfacial location for the neurotransmitter binding sites. The comparison with the 
different AChBP structures, which also bind AChR agonists (e.g., ACh, CCh, nicotine, etc.) and 
competitive antagonists [e.g., α-bungarotoxin (α-BTx), d-tubocurarine, etc.], have confirmed that 
ligand sites are located between two subunits [18,20,24,25,27,48,87,106] (reviewed in [89]). 
Additional comparisons with other members of the superfamily including GABAARs 
[28,33,52,96], GlyRs [62], and 5-HT3Rs [83,84] also support such interfacial location.  
(5) An agonist binding site comprised by several loops (A-F) (reviewed in [7]), which have been 
re-named as “binding segments A-F” because some segments are actually in β-sheet rather than a 
loop conformation (reviewed in [69]). Binding segments A-C form the principal component of the 
agonist binding domain (which is located in the α subunit from AChRs and homologous subunits 
from other receptors), whereas binding segments D-F form the secondary component (which is 
located in the non-α subunit from AChRs and homologous subunits from other receptors). The 
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evidence that supports this structural feature was provided by photoaffinity labeling and site-
directed mutagenesis experiments (reviewed in [7]), and more lately by cysteine- [92] and lysine-
scanning mutagenesis [88], as well as by comparative studies using the recently found AChBP 
structures as templates [see paragraph (4)].  
(6) Four transmembrane segments (M1-M4) per subunit (twenty transmembrane segments in total), 
where the M2 transmembrane segment from each subunit (five M2 segments in total) forms the 
wall of the ion channel. The ion channel is the main domain for the action of noncompetitive 
antagonists from endogenous as well as exogenous origin (reviewed in [5,6,9,10,12-14]). The 
transmembrane domain (including the phospholipid headgroup region) measure about 40 Å. 
Earlier hydropathy analysis suggested that the AChR have four transmembrane segments and that 
each segment is mainly in an α-helix secondary structure. This result has been confirmed by 
electron microscopy aided by computational methods [99,100], photoaffinity labeling (reviewed in 
[13,14]), substituted cysteine accessibility method (reviewed in [21,51], and references therein), 
tryptophan-scanning mutagenesis, as well as by circular dichroism and nuclear magnetic 
resonance spectroscopy (reviewed in [8,21]). However, these ion channels contain significant 
amounts of non-helical structures as well. For instance, β-sheet secondary structures have been 
observed in the external portion of M1 and other segments of M3.  
(7) A “hydrophobic girdle”, the so-called “kink”, in the middle of the M2 segment that is formed 
by residues that are conserved through all superfamily member subunits. This hydrophobic girdle 
constitutes the “gate” that is occluding ion flux in the resting (closed) state. In the activated (open) 
state, the rotation of one or two of the M2 segments would disrupt the hydrophobic interactions 
with adjacent helices allowing the passage of ions through the channel. In this regard, 
anticlockwise rotations in the extracellular domain as well as in the M2 domain were observed in 
refined electron microscopy images when the AChR was activated [100].  
(8) A dynamic mechanism, called “ion channel gating”, where agonist binding provokes a 
conformational change in the protein that finally leads the opening of the intrinsically-associated 
ion channel that is located far apart from the proper ligand binding domain. This modular 
mechanism has been studied in detail in the AChR by Auerbach’s laboratory. The main 
conclusion from these studies is that the chemical signal triggered by ACh binding is locally 
transmitted to the extracellular loop formed between M2 and M3 segments, the M2-M3 linker 
(reviewed in [21,30,31]), as a “conformational wave” that finally reaches the ion channel [45] 
(reviewed in [44]).  
Based on the evidence provided by low resolution electron microscopy, a concerted 
anticlockwise rotation of all extracellular domains has been hypothetized as a plausible 
mechanism for gating [98]. Additional evidence has been shown in other receptor members as 
well. For instance, electrostatic interactions were found between a Lys located in the M2-M3 
linker and acidic residues located in the Cys-loop and in the loop 2 from the GABAAR [52]. 
Homologous residues in the GlyR [1] and the 5-HT3R (reviewed in [72]) were also found to be 
critical in the gating process.    
(9) A desensitization process, where the prolonged exposure of the receptor to agonists as well as 
some competitive and noncompetitive antagonists produces a conformational change in the 
protein that finally leads to a refractory state where the agonist does not open the ion channel 
Mar. Drugs 2006, 4                                     60 
 
 
(reviewed in [82]). This conformational state is depicted in Fig. 6. Qualitatively, the 
desensitization process is similar among the members of the Cys-loop receptor superfamily. 
Desensitization might be very important in the prevention of citotoxicity, in the process of 
nicotine addiction, or in other pathological states (reviewed in [82]). For instance, a Ser248 to Phe 
mutation in the pore domain of the α4 subunit results in faster desensitization of α4β2 AChRs 
causing a type of human cortical epilepsy [107]. 
(10) A small cytoplasmic domain formed by the loop between M3 and M4 of variable length 
(from 80 to 265 amino acids). This region contains the greatest sequence divergence among the 
members of this receptor superfamily. This region is very important for receptor modulation by 
phosphorylation-deposphorylation processes (reviewed in [21,49,93]). For instance, tyrosine 
kinases have been found to reduce nicotine-induced currents, whereas phosphotyrosine 
phosphatases have been found to enhance nicotine-induced currents in chromaffin cells [105]. 
Receptor phosphorylation by serine/threonine and/or tyrosine kinases also increases the 
desensitization rate in several members of this LGIC superfamily (reviewed in [49,93]). 
The anchorage of certain receptors to the cytoskeleton is also mediated by the interaction of 
non-receptor proteins with the cytoplasmic domain. Among them we can name rapsyn for AChRs 
(reviewed in [108]) and the tubulin-binding element gephyrin for both GABAARs and GlyRs 
(reviewed in [21,57,73]). Protein-protein contacts may affect receptor assembly, trafficking, 
clustering, targeting, modulation, and turnover, among other processes. 
Finally, the cytoplasmic domain is considered an additional determinant for ion channel 
conductance (reviewed in [80]). Using different 5-HT3R chimaeras, a novel determinant of single-
channel conductance was located to a putative amphipathic helix (the ‘HA stretch’), apart from the 
M2 domain. Key residues may be components of narrow openings within the inner vestibule of 
the channel, which contribute to the permeation pathway.  
(11) And finally, an extracellular location for the very short C-terminal. This small area is 
involved, at least in certain neuronal-type AChRs (e.g., α4β2 and α4β4), in the binding of 
neurosteroids [34,79] (reviewed in [5,6,9,10,13,14]). Neurosteroids are molecules synthesized in 
the CNS that modulate some of the functions of this receptor superfamily. For instance, 17β-
estradiol may enhance the activity of α4β2 and α4β4 neuronal AChRs [34,79] (reviewed in 
[5,6,9,10,13,14,49,60]). GABAAR function is also enhanced by different neurosteroids (reviewed 
in [14,16]), which presents therapeutical opportunities for the treatment of several mood disorders. 
Opposite to that, neurosteroids other than 17β-estradiol (e.g., progesterone, hydrocortisone, etc.) 
inhibit noncompetitively several AChRs by interacting with the lipid-protein interface (reviewed 
in [5,6,9,10,13,14,49]).  
Since one of the topics covered in this special issue includes the action of different marine drugs on 
distinct AChRs, we will give more detailed information on the structure and function of the AChR 
family.  
 
5.1. The Nicotinic Acetylcholine Receptor Family 
 
The AChR family can be subdivided in two main receptor types (see Table 4): (a) the muscle-type 
AChR that is formed by a combination of four different subunits in a stoichiometry that depends on the 
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developmental stage of the muscle. The muscle in the embryonic stage has receptors (as well as the 
Torpedo or Electrophorus receptor) with the stoichiometry α12β1γδ, whereas muscle cells in the adult 
stage has receptors with the stoichiometry α12β1εδ. Both receptors are arranged in an anticlockwise 
manner as αγ/εαδβ; and (b) neuronal-type AChRs which can be formed by the combination of several 
α (α2-α10) and β (β2-β4) subunits. Functional, active homomeric AChRs are formed only by subunits 
α7, α8, or α9, whereas heteromeric AChRs can be shaped by a combination of two, three, or even four 
different subunits (reviewed in [7,75]).  
From the functional point of view, the activation of AChRs provokes an excitatory response on the 
cell because these receptors are connected to a cation-selective channel that allows the passage of 
cations such as Na+, K+, or Ca2+. The activation of these ion channel receptors increases cation 
permeability which subsequently produces membrane depolarization. Depolarization of the membrane 
provokes specific physiological responses on each involved cell. For instance, if the muscle membrane 
depolarization is large enough, an action potential is elicited. This action potential propagates from the 
neuromuscular junction all over the muscle fiber. During the propagating action potential the release of 
Ca2+ ions from intracellular stores in the muscle cell (e.g., ER) is stimulated. The final response in the 
muscle is the contraction of its myofibrils. On the other hand, in neurons, the excitatory signal 
provided by the activation of the cation channel is summed with other signals (including inhibitory 
ones provided by the activation of anionic channels) and subsequently re-directed to another neuron or 
to an endocrine gland cell as a nerve action potential. 
The AChR family is implicated in several important physiological functions (reviewed in [70]). For 
instance, AChRs may directly or indirectly act on cognition, learning, memory and attention, 
neurodegeneration, pain perception, reward, anxiety and depression control, body temperature, 
auditory function development, control of voluntary motion, respiration, sleep and wakefulness, 
protective responses to stress (e.g., hypoxia), cardiovascular and gastrointestinal tract, as well as on 
muscle contraction and tone. From the pathophysiological point of view, AChRs are involved in 
different neurological disorders including Alzheimer’s and Parkinson’s disease, schizophrenia, drug 
addiction, Tourette’s syndrome, myasthenia gravis and myasthenic syndromes, depression, anxiety, 
ulcerative colitis, attention-deficit hyperactivity disorder, and neuroinflammation [97], as well as on 
different types of epilepsies, including nocturnal lobe, juvenile myoclonic, and catamenial epilepsy 
(reviewed in [49,68,70]).  
Several members from the AChR family are targets for the pharmacological action of different 
natural toxins (reviewed in [7,11]). The list of alkaloids that act as agonists includes (-)nicotine 
(obtained from the leaves of the tobacco plant Nicotiana tabacum), (+)anatoxin-a (obtained from the 
blue-green algae Anabena flos-aquae), (-)cytisine (obtained from the plant Thermopsis alterniflora), 
(±)epibatidine (obtained from the skin of the Ecuadorian frog Epipedobates tricolor), lobeline 
(obtained from the plant Lobelia inflata), and anabaseine (obtained from Nemertine marine worm 
species and from venom glands of certain ants). Among competitive antagonists we can name 
alkaloids such as d-tubocurarine (obtained from the bush Chondrodendron tomentosum), 
methyllycaconitine (obtained from the seeds of the plant Delphinium brownii), and dihydro-β-
erythroidine (obtained from different Erythrina plant species), snake polypeptides such as α- and κ-
bungarotoxins [obtained from different Elapidae (e.g., the many-banded krait Bungarus multicinctus) 
and Hydrophiidae (sea snakes) species] and cobrotoxins (e.g., from Naja naja siamensis), as well as 
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marine toxins such as lophotoxins (obtained from gorgonian corals such as Lophogorgia and 
Pseudopterogorgia), neosurugatoxin (obtained from the Japanese ivory shell Babylonia japonica), as 
well as α- and αA-conotoxins (obtained from several Conus species). Finally, among noncompetitive 
antagonists we can quote the alkaloid ibogaine (obtained from the shrub Tabernanthe iboga), and the 
psi-conotoxin PIIIE (obtained from C. purpurascens). For more details on conotoxins see the 
minireview by Layer and McIntosh in this special issue. 
Although some toxins bind to different AChRs in a nonspecific manner, several toxins present very 
high affinity and high specificity for certain receptor types, pointing out the importance for potential 
therapeutic uses. In this regard, Kem and colleagues review the activity of benzylidene-anabaseine 
derivatives as partial specific agonists of the α7 AChR as well as the noncompetitive mechanism for 
these compounds in muscle-type AChRs. In addition, Wonnacott and Gallagher cover the structure-
function relationship for anatoxin-a. 
Since this special issue includes marine drugs interacting neither with 5-HT3Rs, GABAARs, 
GABACRs, and GlyRs (members from the Cys-loop receptor superfamily), nor with members from the 
GluR or P2XnR superfamily, we will not cover these receptors any further. 
6. Conclusions 
Since the decade of 1900, where the concept of neurotransmission was first defined, until now, a great 
deal of information on the synapse structure and function has been accumulated with the help of 
different approaches from different research areas such as molecular and cell biology, biochemistry, 
electrophysiology, biophysics, and genetically-altered animals. One of the most important entities for 
synapse functioning, ion channels, is the focus of this special issue. Since the structural 
characterization of AChRs, the archetype of the LGIC receptor superfamilies, until today, additional 
LGIC as well as VGIC superfamilies have been extensively studied. In this regard, our actual 
knowledge on the structure and function of different marine drugs acting on LGIC as well as on VGIC 
superfamilies will pave the way to new therapies for the treatment of distinct neurological diseases. 
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